The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Ipsen; Ipsen; Ipsen; Ipsen; Lilly; Lilly; Lilly; Lilly; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
Speakers' Bureau - Bayer; Bayer; Bayer; Bayer; Ipsen; Ipsen; Ipsen; Ipsen; Lilly; Lilly; Lilly; Lilly; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical
Research Funding - Bayer; Bayer; Bayer; Bayer
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Ipsen; Ipsen; Ipsen
 
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Ipsen; Ipsen; Ipsen; Lilly; Lilly; Lilly; Lilly; Roche; Roche; Roche; Roche
Research Funding - Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Ipsen; Ipsen; Ipsen; Ipsen; Lilly; Lilly; Lilly; Lilly; Roche; Roche; Roche; Roche
Pattern of progression in advanced HCC treated with ramucirumab/placebo: Results from two randomized phase III trials (REACH/REACH-2).
 
Maria Reig
No Relationships to Disclose
 
Peter R. Galle
No Relationships to Disclose
 
Masatoshi Kudo
Honoraria - Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Eisai; MSD; MSD; MSD; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; MSD; MSD; MSD; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); EA Pharma (Inst); EA Pharma (Inst); EA Pharma (Inst); EA Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Otsuka (Inst); Otsuka (Inst); Otsuka (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst)
Expert Testimony - Novartis; Novartis; Novartis; Novartis
 
Josep M. Llovet
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Can-Fite BioPharma; Can-Fite BioPharma; Can-Fite BioPharma; Can-Fite BioPharma; Celsion; Celsion; Celsion; Celsion; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Fortress Biotech; Fortress Biotech; Fortress Biotech; Fortress Biotech; Glycotest; Glycotest; Glycotest; Glycotest; Incyte; Incyte; Incyte; Incyte; Leerink; Leerink; Leerink; Leerink; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Midatech Pharma; Midatech Pharma; Midatech Pharma; Midatech Pharma; Navigant Consulting; Navigant Consulting; Navigant Consulting; Navigant Consulting; Nucleix; Nucleix; Nucleix; Nucleix; Spring Bank; Spring Bank; Spring Bank; Spring Bank
Research Funding - Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer
 
William R. Schelman
Employment - Lilly; Lilly; Lilly; Lilly
Stock and Other Ownership Interests - Lilly; Lilly; Lilly; Lilly
 
Kun Liang
Employment - Lilly; Lilly; Lilly; Lilly
Stock and Other Ownership Interests - Lilly; Lilly; Lilly; Lilly
 
Chunxiao Wang
Employment - Lilly; Lilly; Lilly; Lilly
Stock and Other Ownership Interests - Lilly; Lilly; Lilly; Lilly
 
Ryan C. Widau
Employment - Lilly; Lilly; Lilly; Lilly
Stock and Other Ownership Interests - Lilly; Lilly; Lilly; Lilly
 
Paolo Abada
Employment - Lilly; Lilly; Lilly; Lilly
Stock and Other Ownership Interests - Lilly; Lilly; Lilly; Lilly
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst)